Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Completed · Phase 2

Conditions studied: Parkinson Disease, Dyskinesia, Drug-Induced, Levodopa

In brief

The purpose of this study is to generate long-term safety, tolerability and efficacy data for AFQ056 in patients who have participated in and completed any AFQ056 phase II study in PD-LID (Parkinson's disease, L-dopa induced dyskinesias).

Key facts

Study ID

NCT01173731

Run by

Novartis Pharmaceuticals

People needed

66

Starts

2010-10-01

Expected to finish

2013-10-01

Last updated by the study team

2020-12-23

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Outpatients with Parkinson's disease (PD), treated with L-Dopa, experiencing dyskinesias who have been eligible for, participated in and completed an AFQ056 phase II core study.

You may not qualify if…

• Surgical treatment for PD
• Cancer within the past 5 years (other than localized skin cancer and prostate cancer that has been effectively treated)
• Advanced, severe or unstable disease (other than PD) that may interfere with the study outcome evaluations
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Novartis Investigative Site — Sunnyvale, California, United States
• Novartis Investigative Site — Englewood, Colorado, United States
• Novartis Investigative Site — Indianapolis, Indiana, United States
• Novartis Investigative Site — Heidelberg, Victoria, Australia
• Novartis Investigative Site — Parkville, Victoria, Australia
• Novartis Investigative Site — Prahran, Victoria, Australia
• Novartis Investigative Site — Ottawa, Ontario, Canada
• Novartis Investigative Site — Gatineau, Quebec, Canada
• Novartis Investigative Site — Greenfield Park, Quebec, Canada
• Novartis Investigative Site — Clermont-Ferrand, France
• Novartis Investigative Site — Lille, France
• Novartis Investigative Site — Pessac, France
• Novartis Investigative Site — Bochum, Germany
• Novartis Investigative Site — Dresden, Germany
• Novartis Investigative Site — Kassel, Germany
• Novartis Investigative Site — Marburg, Germany
• Novartis Investigative Site — München, Germany
• Novartis Investigative Site — Stadtroda, Germany
• Novartis Investigative Site — Tübingen, Germany
• Novartis Investigative Site — Lido di Camaiore, LU, Italy
• Novartis Investigative Site — Roma, RM, Italy
• Novartis Investigative Site — Naples, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.